Biotech Values

[biomaven0]

ITMN:

>>If the Bosentan trial meets their end point would you be less inclined to approve?

No, as I believe what we call "IPF" is actually multiple diseases, in which case it is likely that different drugs will work for different endpoints.

I think there is a good chance in many of these trials that a fair number of patients have some completely different underlying condition. "True" IPF is supposed to be rapidly progressive and fatal within a few years - that's not always what we have seen in the placebo groups in IPF trials. We really need some biomarkers to figure out the different subgroups.

Peter